Next Article in Journal
Venetoclax–Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview
Previous Article in Journal
Moderate Immune-Related Liver Injury Is a Good Factor in Patients with Hepatoma Under Atezolizumab Plus Bevacizumab
 
 
Guidelines

Article Versions Notes

Cancers 2025, 17(19), 3158; https://doi.org/10.3390/cancers17193158
Action Date Notes Link
article xml file uploaded 29 September 2025 06:18 CEST Original file -
article xml uploaded. 29 September 2025 06:18 CEST Update -
article pdf uploaded. 29 September 2025 06:19 CEST Version of Record https://www.mdpi.com/2072-6694/17/19/3158/pdf-vor
article html file updated 29 September 2025 06:20 CEST Original file -
article xml file uploaded 30 September 2025 03:32 CEST Update -
article xml uploaded. 30 September 2025 03:32 CEST Update https://www.mdpi.com/2072-6694/17/19/3158/xml
article pdf uploaded. 30 September 2025 03:32 CEST Updated version of record https://www.mdpi.com/2072-6694/17/19/3158/pdf
article html file updated 30 September 2025 03:35 CEST Update https://www.mdpi.com/2072-6694/17/19/3158/html
Back to TopTop